Oncology Business Management | Specialty

AUA2015: Biomarkers, Enzalutamide, and ARN509

May 17th 2015

Combining and Sequencing Sipuleucel-T in CRPC

May 17th 2015

Committee of Elite Oncologists Selects World's Best to Receive OncLive's 2015 Giants of Cancer Care Awards

May 14th 2015

Individuals chosen by this elite committee to receive the 2015 Giants of Cancer Care award for outstanding contributions in the field of oncology will be announced Friday, May 29, during the 3rd Annual Giants of Cancer Care Award Ceremony.

Doctors Unwilling to Trust Similarity of Biosimilars

May 13th 2015

The FDA's approval in March of the first biosimilar drug for the US market has aroused much concern among physicians.

Doctors May Lose Care Control to Integrated Delivery Networks

May 9th 2015

The healthcare market has been consolidating in recent years with practice mergers, hospital partnerships, and acquisitions or affiliations with primary care and specialist practices.

First FDA-Approved Biosimilar Blocked From Entering US Market

May 8th 2015

The first FDA-approved biosimilar, Zarxio, has been blocked from reaching US markets by an injunction from Amgen, the manufacturer of the G-CSF analog counterpart, Neupogen (filgrastim).

FDA Grants Venetoclax Breakthrough Designation for CLL

May 7th 2015

The FDA has granted a breakthrough therapy designation to the Bcl-2 inhibitor venetoclax (GDC-0199/ABT-199) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia who harbor a 17p deletion (del[17p]).

Cancer Drug Spending Hits $100 Billion

May 6th 2015

Earlier diagnosis, longer treatment durations, and increased effectiveness of treatments helped to boost spending on cancer medicines to the $100 billion threshold in 2014, a rise of 10.3% for the year, and up markedly from $75 billion five years earlier.

More Effort Needed to Understand Value Breadth of Molecular Testing

May 6th 2015

As the use of testing increases, so does the importance of understanding exactly what it can do for your patients and how to get the most out of the results.

Votes Are Cast for OncLive's Giants of Cancer Care Awards from Among the Biggest Names in Cancer. Who Will Be the Winners?

April 30th 2015

Deliberations are complete and final votes cast for the winners of the 2015 Giants of Cancer Care Award recognizing individuals who have achieved landmark success in the field of oncology.

FDA Panels Support Approval of T-VEC in Melanoma

April 29th 2015

In a combined decision, members of the FDA's Oncologic Drugs Advisory Committee and Cellular, Tissue and Gene Therapies Advisory Committee voted 22-1 to recommend approval of the oncolytic immunotherapy talimogene laherparepvec (T-VEC) as a treatment for patients with advanced melanoma.

Dr. Alan Miller on Benefits of Liquid Biopsy

April 29th 2015

Alan M. Miller, MD, PhD, Director of the Baylor Charles A. Sammons Cancer Center and Chief of Oncology for the Baylor Health Care System discusses the benefits of liquid biopsy.

Improving Treatment Requires Collaboration and Transparency

April 26th 2015

Application of Payment Reform Models in Oncology

April 26th 2015

Practical Application and Utility of EMRs

April 26th 2015

Coverage Decisions for Off-Label Treatments

April 26th 2015

Cost Containment's Impact on Oncology Practices

April 26th 2015

Assessing the Cost of Cancer Care

April 26th 2015

Bundled Payments in Community Oncology

April 26th 2015

Moving Away From Traditional Payment Models in Oncology

April 26th 2015